NEWS & VIEWS
In May this year, you were the inaugural recipient of the 'Epigenetic Medicine Award', which honors a researcher/physician who has used the principles of epigenetics to produce a signifi cant breakthrough in medical understanding. Can you describe your work that led to such an achievement in epigenetics?
There is now compelling human epidemiological and animal experimental data indicating that the risk of developing adult-onset diseases and neurological disorders is infl uenced by persistent adaptations to prenatal and early postnatal exposure to environmental conditions such as nutritional privation [1] . However, the mechanism by which these two disparate periods of life are linked was unknown until we published our seminal paper in 2003 using the viable yellow agouti (A vy ) mouse [2] .
This novel strain of mice harbors a metastable Agouti gene because of an upstream insertion of a transposable element. Consequently, genetically identical A vy mice have coat colors ranging from yellow to brown that depend solely upon epigenetic modifications of the transposon (e.g., DNA methylation) rather than genetic mutations in the DNA (FIGURE 1). With the use of this experimental model, we showed for the fi rst time that maternal dietary supplementation during pregnancy, with either methyl donors (i.e., folic acid, vitamin B 12 , choline and betaine) [2] or genistein [3] , alters coat color distribution and decreases adult disease incidence in the offspring by increasing DNA methylation at the Agouti locus; an example of nature via nurture. Moreover, we subsequently showed that these nutritional supplements can counteract the negative epigenome effects caused by environmental exposure to the endocrine disruptor, bisphenol A [4] . 
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of ionizing radiation. I found his lectures so inspirational that I asked him if I could work in his laboratory to learn more about radiation biology. The positive experience of working in Professor Clifton's laboratory as an undergraduate student changed my career dramatically because it convinced me to do graduate research under his tutelage in the biological rather than physical sciences. When I joined the faculty at Duke University (NC, USA), I met George Michalopoulos who is now Chairman and Professor of Pathology at the University of Pittsburgh (PA, USA). We initiated a productive collaboration that resulted in the development of the fi rst clonal assay system for rat hepatocytes [5] , and an enzymatic method still used today for reproducibly isolating large numbers of hepatocytes from human liver [6] . More importantly, George introduced me to the research fi eld of liver carcinogenesis, which ultimately led to my laboratory discovering the first imprinted tumor suppressor gene, the insulin-like growth factor 2 receptor (IGF2R). This discovery signifi cantly altered the direction of my research because it required us to enter the emerging fi elds of epigenetics and genomic imprinting.
You are currently the Director of your laboratory in the Department of Radiation Oncology at Duke University. Can you briefl y discuss the research projects that are being carried out in your laboratory?
The mouse is immensely popular as a model for human diseases; however, it may not be a suitable choice for risk assessment or developing preventative and therapeutic approaches for human diseases when imprinting deregulation plays an important role in the disease pathogenesis. This is because the repertoire of imprinted genes in mammals is markedly species dependent [7] [8] [9] [10] .
With the use of computer learning algorithms, we have recently identifi ed genes from throughout the human genome with high probability of being imprinted [10] . We are now experimentally screening these candidate imprinted genes for those that are associated with differentially methylated cis-acting imprint regulatory elements, and are expressed from only one parental chromosome -characteristics required of genes truly imprinted. By projecting these laboratory-confi rmed imprinted genes onto the landscape of disease risk as defi ned by linkage studies, we can then begin studies to determine Your research group was the fi rst to demonstrate that the IGF2R gene is a tumor suppressor. Can you explain the signifi cance of this discovery, and the progress of the research since this discovery was made?
The IGF2R gene was the fi rst tumor suppressor gene identifi ed to also be imprinted and expressed from only one parental allele. Geneticist Alfred G Knudson's 'two-hit hypothesis' of cancer development states that since most of the genes that regulate cancer are still effective even when one of the two copies is disabled, going from a normal phenotype to a cancer phenotype requires two mutations, or 'hits' to a cancercontrolling gene [11] . A pre-existing mutation in one of the gene copies would act as one hit, but so would an imprint. Thus, unlike genes expressed from both chromosomes, only a single genetic mutation or epigenetic event is required to inactivate an imprinted tumor suppressor gene.
We also demonstrated that IGF2R imprinting was initiated approximately 180 million years ago, apparently in a common ancestor to Therian mammals [12] , but was subsequently lost approximately 75 million years ago with the evolution of the near primates that ultimately gave rise to humans [7] . Since IGF2R is mono allelically expressed in mice, but expressed from both alleles in humans, its probability of being inactivated is species dependent. This fi nding clearly shows that we need to be careful in interpreting results when the mouse is used as a surrogate for toxicological risk assessments and as models for investigating the pathogenesis of human diseases. We also now have evidence that IGF2R mutation increases the resistance of head and neck cancer to radiotherapy [13] , and alters cognitive ability in both mice and humans in a sexdependent manner.
How did you become involved in the burgeoning fi eld of genomic imprinting?
In the early 1990s, we were investigating phenobarbital promotion of liver tumours in rats [14] . Interestingly, we discovered that the expression of IGF2R was markedly reduced early in the carcinogenesis process. This was particularly interesting because this receptor is involved in the activation of the growth inhibitor, transforming growth factor β (TGFβ), and the degradation of the growth factor, IGF2. Thus, we suggested that IGF2R functions as a tumor suppressor gene, a postulate further strengthened by our later demonstration that IGF2R is frequently mutated in a number of human tumors [15, 16] .
While we were studying the role that IGF2R plays in the etiology of cancer, it was identifi ed by Denise Barlow to be imprinted in mice [17] . Genomic imprinting results in monoallelic expression of genes in a parent-of-origin dependent manner. Since imprinted genes are functionally haploid, only a single genetic mutation or epigenetic event (e.g., DNA methylation) is required to significantly alter their function [18, 19] . Thus, imprinted genes are potential disease susceptibility loci. This is why we have focused our research efforts since then on the epigenetic regulation of imprinting, and the role its deregulation plays in disease pathogenesis.
What, in your opinion, is the most exciting research currently being conducted in epigenomics?
The elegant behavioral studies by Michael Meaney, Moshe Szyf, and their colleagues at McGill University (Canada) are particularly interesting and important. They demonstrate that generation-to-generation attainment of the nurturing behaviors of pup licking and grooming and arch-back nursing in rats are not germline inherited. Rather, they are passed on to the offspring directly from the mother during the fi rst week of postnatal life through the induction of DNA methylation and histone modifi cations at the nerve growth factor inducible protein A (NGFIA) transcription-factorbinding motif present in the promoter of the brain-specifi c gluco corticoid receptor (GR) in the hippocampus of the brain [20] . Moreover, the inherent plasticity of the epigenome allows for the reversal of these modifi cations in adulthood by exposure to epigenetic therapeutic agents [21] . 
These investigators have now made the startling discovery in humans that the protein synthesis machinery in the suicide brain is aberrantly regulated in the hippo campus because of a promoter-wide increase in the DNA methylation of rRNA genes [22] . The suicide subjects in this study had a history of early childhood neglect and abuse, whereas, the control victims died accidentally and had no history of abuse or neglect. These fi ndings are consistent with the intriguing possibility that early life events can alter the epigenetic status of genes that control neural functions, thereby contributing to individual differences in suicide risk and possibly other human behaviors.
Where do you think your research efforts will be focused in the next 5 years?
If the unique importance of imprinting in the genesis of human diseases is to be deciphered, we will need to adhere to the advice of English poet, Alexander Pope, who wrote over three centuries ago, "The proper study of Mankind is Man".
There is evidence that imprinted genes are involved in the developmental origins of adult human diseases [18, 19] . Consequently, we are now focusing our research efforts on the genomewide identifi cation of imprinted genes in the human. In collaboration with Alex Hartemink at Duke University, we recently developed computer-learning algorithms that predicted the presence of 600 imprinted genes in mice [8] , but only 156 imprinted genes in humans [10] . Not only is there evidence that humans have fewer imprinted genes than mice, but the imprinted gene repertoires overlap only a mere thirty percent.
Thus, diseases that result from environmentally-induced imprinting dys regulation would be expected to be species-dependent, supporting the importance of our present research efforts aimed at defi ning the human 'imprintome' -the cis-acting differentially methylated imprint regulatory elements in the human genome. Once defi ned, we will determine those imprinted genes whose epigenetic dysregulation is mechanistically involved in the etiology of human diseases and neurological disorders, such as autism, bipolar disorder, cancer, diabetes, obesity and schizophrenia. Although this is an ambitious under taking, its successful completion is critical for understanding the developmental origins of human disease susceptibility.
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